David Cosgrove

Compass Oncology — United States

Medicine · Health Sciences

39h-index8.0kcitations120works1.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hepatocellular Carcinoma Treatment and Prognosis(34), Colorectal Cancer Treatments and Studies(23), Cholangiocarcinoma and Gallbladder Cancer Studies(22), Cancer Genomics and Diagnostics(19), Cancer Mechanisms and Therapy(10)

Publications120 total

ER degradation for ER+/HER2– advanced or metastatic breast cancer: a phase 1 trial
Nature Communications·2025Open Access
ER degradation for ER+/HER2‒ advanced or metastatic breast cancer: a phase 1 trial
2025Open Access
Real-world treatment patterns and outcomes among patients initiating sequential regorafenib and trifluridine/tipiracil ± bevacizumab in patients with metastatic colorectal cancer in a US community setting (SEQRT2)
Frontiers in Oncology·2025· 1 citedOpen Access
Biomarker testing, treatment patterns and outcomes in previously treated pMMR or non-MSI-H metastatic colorectal cancer patients
Future Oncology·2025· 1 citedOpen Access
Atezolizumab Plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Real-World Experience From a US Community Oncology Network
Journal of Hepatocellular Carcinoma·2025· 4 citedOpen Access
A phase III randomized study of first-line NUC-1031/cisplatin vs. gemcitabine/cisplatin in advanced biliary tract cancer
Journal of Hepatology·2025· 7 citedOpen Access
Real-world (RW) treatment patterns and clinical outcomes of patients treated with sequential regorafenib and trifluridine/tipiracil ± bevacizumab (BEV) for metastatic colorectal cancer (mCRC) in the United States (US) community oncology setting: The SEQRT2 study.
Journal of Clinical Oncology·2025· 1 cited
Real-world treatment patterns and outcomes for patients with neoadjuvant treatment between 2019-2022 for gastric or gastroesophageal junction cancer (GC/GEJC) in the US community setting.
Journal of Clinical Oncology·2025
637P AC699, a novel chimeric estrogen receptor degrader, in a phase I study in breast cancer
Annals of Oncology·2024
COMPANION-002 A clinical trial of investigational drug CTX-009 plus paclitaxel vs paclitaxel in second line advanced BTC
Future Oncology·2024· 3 citedOpen Access
Preliminary results from a phase 1 study of AC699, an orally bioavailable chimeric estrogen receptor degrader, in patients with advanced or metastatic breast cancer.
Journal of Clinical Oncology·2024· 7 cited
HSD106 Metastatic Colorectal Cancer (mCRC) Patients Treated with Later Lines of Treatment (LOT): A Retrospective Analysis By Race and Ethnicity in the United States (US) Community Oncology Setting
Value in Health·2024Open Access
Abstract CT075: A Phase 1 trial evaluating AC699, an orally bioavailable chimeric estrogen receptor degrader, in patients with advanced or metastatic breast cancer
Cancer Research·2024· 1 cited
Abstract 927: Real-world (RW) biomarker characteristics and clinical outcomes in pre-treated non-MSI-H/dMMR metastatic colorectal cancer (mCRC) patients
Cancer Research·2024
Atezolizumab plus bevacizumab (A+B) in patients with unresectable hepatocellular carcinoma (uHCC): Real-world experience from a US community oncology network.
Journal of Clinical Oncology·2024· 1 cited
Real-world biomarker testing patterns among patients with metastatic colorectal cancer (mCRC) treated with later lines of therapy (LOT) in the United States (US) community oncology setting.
Journal of Clinical Oncology·2024
A phase 2/3 randomized study of CTX-009 combination in 2L biliary tract cancer: COMPANION-002.
Journal of Clinical Oncology·2024
Real-world treatment patterns and unmet need in patients with previously treated metastatic colorectal cancer that is not MSI-H or dMMR.
Journal of Clinical Oncology·2024
Abstract B048: NUC-3373 in combination with irinotecan (NUFIRI) or oxaliplatin (NUFOX) and bevacizumab for second-line treatment of patients with advanced colorectal cancer (NuTide:302)
Molecular Cancer Therapeutics·2023· 1 cited
A Phase 1a/b Trial of Luxeptinib (CG-806) in Patients with Relapsed/Refractory B-Cell Malignancies or Acute Myeloid Leukemia and Evaluation of New G3 Formulation
Blood·2023· 6 cited
page 1 of 6Next →

Frequent Co-authors

Timothy M. Pawlik(19), Ihab R. Kamel(18), Joseph M. Herman(15), Jean-François H. Geschwind(14), Timothy M. Pawlik(7), Diane K. Reyes(5), Nikhil Bhagat(5), John P. Gustin(5), Allen Lee Cohn(4), Rebecca M. Dodson(4), Abde M. Abukhdeir(4), Josh Lauring(4), Joseph P. Garay(4), Hiroyuki Konishi(4), Morassa Mohseni(4), Michaela J. Higgins(4), Michael A. Choti(4), Omar Hyder(4), Celia P. Corona‐Villalobos(4), Vivek Gowdra Halappa(4)